CNS PharmaceuticalsCNS PharmaceuticalsCNS Pharmaceuticals
  • Brain
    • Glioblastoma
    • Anthracyclines
    • Blood Brain Barrier
  • Technology
    • Berubicin
    • Pipeline
  • Team
    • Management
    • Board
  • About Us
  • Contact
  • Investors
  • Sign Up

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8:30am ET

Dec 18, 2020 8:00am EST

CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin

Dec 17, 2020 4:05pm EST

CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

Dec 17, 2020 9:00am EST

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy

Nov 24, 2020 8:00am EST

CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting

Nov 19, 2020 8:00am EST

CNS Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium

Nov 18, 2020 8:00am EST

CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin

Nov 17, 2020 8:00am EST

CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4:30 PM ET Today

Nov 12, 2020 8:00am EST

CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review

Nov 09, 2020 8:00am EST

CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial

Oct 29, 2020 8:00am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...12
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    © 2023 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma

    • Brain
      • Glioblastoma
      • Anthracyclines
      • Blood Brain Barrier
    • Technology
      • Berubicin
      • Pipeline
    • Team
      • Management
      • Board
    • About Us
    • Contact
    • Investors
    • Sign Up